8 recruiting, 2 completed, 2 unknown, 1 active not recruiting. 6 Phase 1, 3 Phase 2, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Completed 2, Active not recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Unknown 1 |
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow High Grade Serous Ovarian Cancer: new trials by email Literature Review of High Grade Serous Ovarian Cancer trials Research Report on High Grade Serous Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive | Recruiting | Hellenic Cooperative Oncology Group | 200 | 2026-07-10 | 2026-10-22 | |
| A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types IDE034 - Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer | Phase 1 | Recruiting | IDEAYA Biosciences | 150 | 2026-02-24 | 2026-06-18 |
| Minimal Residual Disease in Solid Malignancies ctDNA detection - Breast Cancer, Non Small Cell Lung Cancer | Not applicable | Not yet recruiting | European Institute of Oncology | 840 | 2025-12-01 | 2025-12-05 |
| Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer Dose Level 2 (starting dose), Dose Level 1, Dose Level -1 - High Grade Serous Ovarian Cancer | Phase 1 | Recruiting | Institute of Cancer Research, United Kingdom | 33 | 2025-08-01 | 2025-08-13 |
| Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer High Grade Serous Ovarian Cancer, Cervical Cancer Screening | Recruiting | Institut Claudius Regaud | 50 | 2025-01-05 | 2026-09-16 | |
| Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma High Grade Serous Ovarian Cancer | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 150 | 2024-03-20 | 2025-01-15 | |
| Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging Blood sample and tissue sample - High Grade Serous Ovarian Cancer | Not applicable | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 120 | 2023-12-19 | 2025-02-12 |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib Avutometinib (VS-6766) + defactinib - Endometrioid Cancer, Mucinous Ovarian Cancer | Phase 2 | Recruiting | University of Oklahoma | 55 | 2023-02-06 | 2025-10-22 |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Genmab | 952 | 2022-12-07 | 2026-10-07 |
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Upifitimab rilsodotin, Placebo - High Grade Serous Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mersana Therapeutics | 20 | 2022-06-23 | 2023-10-26 |
| miRNAs in High Grade Serous Ovarian Cancer High Grade Serous Ovarian Cancer | Unknown | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 150 | 2021-10-01 | 2021-12-06 | |
| NUVOLA TRIAL Open-label Multicentre Study Olaparib, Paclitaxel, Carboplatin - High Grade Serous Ovarian Cancer | Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 35 | 2019-12-01 | 2020-02-07 |
| A Phase I Trial of LY3143921 Hydrate in Solid Tumours LY3143921 hydrate - Colorectal Cancer, High Grade Serous Ovarian Cancer | Phase 1 | Completed | Cancer Research UK | 69 | 2017-06-21 | 2026-08-18 |
| "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide - Recurrent, Platinum-resistant | Phase 1 | Active not recruiting | University Health Network, Toronto | 3 | 2015-01-01 | 2026-07-07 |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors Veliparib - Oncology, BRCA Mutated | Phase 1 | Completed | AbbVie | 71 | 2013-03-18 | 2017-11-21 |
| Expanded Access to Veliparib Veliparib - Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC) | No longer available | AbbVie | 2022-05-24 |
Ovarian Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (3) · Fallopian Tube Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Recurrence (2) · Uterine Cervical Neoplasms (2) · Esophageal Squamous Cell Carcinoma (1) · Genomic Instability (1) · Mesothelioma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Papillomavirus Infections (1)
Neoplasms (11) · Neoplasms by Site (11) · Genital Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (9) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Adnexal Diseases (6) · Endocrine Gland Neoplasms (6) · Endocrine System Diseases (6) · Breast Diseases (5) · Gonadal Disorders (5) · Ovarian Diseases (5)
Carboplatin (2) · veliparib (2) · Bevacizumab (1) · Blood Specimen Collection (1) · Cyclophosphamide (1) · Erythromycin (1) · Histocompatibility Testing (1) · Interleukin-2 (1) · Itraconazole (1) · Maximum Tolerated Dose (1) · Paclitaxel (1) · aldesleukin (1) · defactinib (1) · olaparib (1) · pembrolizumab (1)
AbbVie (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · Cancer Research UK (1) · European Institute of Oncology (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Genmab (1) · Hellenic Cooperative Oncology Group (1) · IDEAYA Biosciences (1) · Institut Claudius Regaud (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Institute of Cancer Research, United Kingdom (1) · Mersana Therapeutics (1) · University Health Network, Toronto (1) · University of Oklahoma (1)
United States (4) · Italy (3) · Canada (2) · France (2) · United Kingdom (2) · Australia (1) · China (1) · Greece (1) · Japan (1)
Anna Myriam Perrone (1) · Antonio Marra, MD (1) · Christina Washington, MD (1) · Giovanni Scambia, Prof (1) · Giulio Ricotta, Dr (1) · Giuseppe Curigliano (1) · Lorenzo Montanaro, MD (1) · Luca Mazzarella, MD (1) · Marcus Butler, M.D. (1) · Philip Komarnitsky, MD (1) · Pier Giuseppe Pelicci, MD (1) · Professor Udai Banerji (1) · Robert Burger, MD (1)
PMID 28243955, PMID 29733524, PMID 34131041
2016 (1)